Core Viewpoint - The company, Guangdong Bibet Medical Co., Ltd., is experiencing significant stock price volatility, with a cumulative price deviation of 30% over three consecutive trading days, prompting a review of its operational status and disclosures [5][12]. Group 1: Stock Trading and Price Volatility - The company's stock price has shown abnormal fluctuations, with a cumulative price deviation of 30% recorded on January 5, 6, and 7, 2026, indicating unusual trading activity [5]. - The company has confirmed that its daily operations are normal, with no significant changes in market conditions or internal operations [6]. Group 2: Financial Performance - For the period of January to September 2025, the company reported no sales revenue, with a net loss attributable to shareholders of 107.47 million yuan, showing little change compared to the same period last year [3][14]. - The company emphasizes that its overall operational status remains stable, with no major changes reported [3][14]. Group 3: Product Development and Pipeline - The company focuses on a dual-driven research strategy involving small molecule drugs and small nucleic acid (siRNA) drugs, targeting major diseases such as cancer and metabolic disorders [13]. - Currently, the company has one product approved for market, one in Phase III clinical trials, one approved to start Phase III trials, five in Phase I trials, and others in preclinical research [13]. Group 4: Disclosure and Communication - The company has not identified any significant events that could impact stock prices, and all relevant information has been disclosed through designated media [8][11]. - The company urges investors to rely on information published in specified media outlets and on the Shanghai Stock Exchange website for accurate updates [14].
广州必贝特医药股份有限公司股票交易异常波动公告